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Abstract
Background The German Lipoprotein Apheresis Registry 
(DLAR) has been initiated by members of the Nephrology 
Foundation (WiNe), the German association of kidney cen-
tres (DN), the German society of nephrology (DGfN) and 
additional medical associations taking part in the apheresis 
working group. Its goal is the introduction of a substantial 
database, suitable to provide statistical evidence for the 
assessment of extracorporeal procedures. Data have been 
added to the DLAR since October 2011. In this article, pre-
liminary results are first reported.
Methods and results Data are stored on a secured Internet 
platform. The recorded information comprises mean values 
and rates of change in lipid levels (cholesterol, triglyceride, 
low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol, lipoprotein(a) (Lp(a)) before and af-
ter apheresis therapy, blood/plasma volume, frequency and 
type of adverse effects, medication, vascular events, diagno-
ses and comorbidity. It is collected by participating apher-
esis centres from all over Germany. Up until October 2014, 
a total of 7946 lipoprotein apheresis (LA) treatments of 991 
patients (787 with documented LDL-C and 688 with docu-
mented Lp(a) levels) via 96 medical accounts were docu-
mented and analysed. The current share of Lp(a) patients is 
50.6 % (Lp(a) ≥ 60 mg/dl; n = 348/688). For both LDL-C and 
Lp(a), lowering rates exceeding 60 % have been observed. 
Likely in conjunction with these reduction rates, the prelim-
inary analysis shows a 90 % decline in major adverse coro-
nary events (MACE) as well as a decrease in major adverse 
non-coronary events (MANCE) by 69 %. As before, good 
tolerability and low rates of adverse effects (< 3 %) of LA 
therapy were found.
Conclusions The available numbers suggest in parts very 
good response by the participating centres to the DLAR. Un-
fortunately, there are also centres that have not documented 
any patients so far or LA treatments at all. The benchmark 
values for reduction rates in lipoprotein concentration re-
quired by the directives of the German Federal Joint Com-
mittee (G-BA) have all been met. The decrease in MACE 
and MANCE rates currently observed is very promising. 
However, the comparably short runtime of the registry does 
not allow for high confidence in the current results. Cer-
tainly, reliable data will be extractable in the coming years. 
Given the high interest expressed by European neighbours, 
the extension of the registry to the European level should be 
a future goal for the DLAR as well.
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Bedeutung des Deutschen Lipoproteinapherese-
Registers (DLAR) für die Therapieoption bei Lp(a)-
Erhöhung
Zusammenfassung
Hintergrund Mitglieder der Stiftung für Nephrologie e.V. 
(WiNe), der Verband Deutsche Nierenzentren e. V. (DN), 
die Deutsche Gesellschaft für Nephrologie e. V. (DGfN) 
und weiterer medizinischen Fachgesellschaften der AG-
Apherese riefen das Deutschen Lipoproteinapherese-Regis-
ters (DLAR) zur Schaffung einer breite Datenbasis und Evi-
denz der Behandlungsform ins Leben. Seit Oktober 2011 
werden Daten in das DLAR eingegeben, aus dem eine erste 
Vorstellung der vorläufigen Ergebnisse erfolgt.
Methoden und Ergebnisse Auf einer gesicherte Internet-
Plattform werden Daten zur durchschnittlichen Höhe sowie 
Absenkraten der Lipoproteine, behandelte Blut/Plasmavo-
lumina, Art und Häufigkeit von Nebenwirkungen, Begleit-
medikation, vaskulärer Ereignisse sowie Diagnosen und der 
Komorbiditäten von den teilnehmenden Apheresezentren aus 
Deutschland gesammelt und ausgewertet. Bis zum Oktober 
2014 konnten 991 Patienten (aktuell sind bei 787 Patienten 
LDL-Werte und bei 688 Lp(a) –Werte dokumentiert) mit ins-
gesamt 7946 Lipoproteinapheresen (LA) von 96 teilnehmen-
den ärztlichen Zugängen dokumentiert werden. Zurzeit liegt 
der Anteil von Lp(a)-Patienten bei 50,6 % (Lp(a) ≥ 60 mg/
dl; n = 348/688). Sowohl für LDL-Cholesterin (LDL-C) als 
auch Lp(a) konnten weit mehr als 60 % -Absenkungsraten 
dokumentiert werden. Mutmaßlich mit diesen Absenkungs-
raten assoziiert zeigt sich in den ersten vorläufigen Auswer-
tungen eine Reduktion der Major Adverse Coronary Events 
(MACE) um 90 % bzw. eine Major Adverse Non-Coronary 
Events (MANCE)-Reduktion um 69 %. Erneut konnte eine 
gute Verträglichkeit und geringe Nebenwirkungsrate der 
LA-Therapie von < 3 % dokumentiert werden.
Schlussfolgerung Aus den vorliegenden Zahlen lässt sich 
eine zum Teil sehr gute Resonanz der Registerteilnehmer 
auf das DLAR erkennen. Leider nehmen auch Zentren an 
dem DLAR teil, die bisher entweder keine Patienten oder 
keine Lipoproteinapheresebehandlungen dokumentierten. 
Die in den Richtlinien des Gemeinsamen Bundesausschus-
ses (G-BA) geforderten Lipoproteinabsenkungsraten wer-
den vollständig erfüllt. Die Datenlage der bisher erfassten 
MACE—und MANCE-Reduktionsraten vor und unter LA 
ist sehr vielversprechend, aber dennoch mit Vorsicht bei der 
relativ kurzen Laufzeit des DLAR zu interpretieren. Zuver-
lässige Aussagen lassen sich sicherlich in den kommenden 
Jahren treffen. Angesichts des hohen Interesses auch von 
europäischen Nachbarländern sollte für die Zukunft auch 
ein Ziel des DLAR sein, das Register auf europäische Ebe-
ne auszudehnen.
Schlüsselwörter Lipoproteinapherese · Lipoprotein(a) · 
Lp(a) · Register · Atherosklerose
Abbreviations
DLAR  German Lipoprotein Apheresis Registry
Lp(a)  Lipoprotein(a)
DN  Verband Deutsche Nierenzentren e. V. 
(German association of kidney centres)
DGfN  German Society of Nephrology
WiNe  Scientific Institute for Nephrology
MACE  Major adverse coronary events
MANCE  Major adverse non-coronary events
G-BA  German Federal Joint Committee
KBV  National Association of Statutory Health 
Insurance Physicians
Background
Approximately 400,000 people (ca. 5 %) in Germany may 
be affected by lipid disorders and sequelae [1]. In certain 
lipoprotein and lipid constellations, patients require lipo-
protein apheresis (LA) therapy: especially in patients with 
severe familial hypercholesterolaemia and in cases with no 
response to dietary and lipid lowering therapy, but early 
onset or rapid progressing coronary heart disease (CHD), 
apoplexy or peripheral arterial disease (PAD). More than 
2000 patients in Germany receive this extracorporeal treat-
ment. This form of apheresis is designed to remove low-
density lipoprotein cholesterol (LDL-C), lipoprotein(a) 
(Lp(a)) and other factors facilitating atherosclerosis from 
the blood. Since 1974, six different methods for LA have 
been developed. All LA techniques approved in Germany 
meet the quality standards required by the German Federal 
Joint Committee (G-BA) in that they achieve a minimum 
60 % reduction of LDL-C and Lp(a) concentrations in a 
single treatment [2]. The extracorporeal therapy is received 
weekly in most cases as an ambulant treatment in the dialy-
sis facility of a resident nephrologist, in specialised hospi-
tals or university clinics as well as in respective charities.
Members of the Nephrology Foundation (WiNe), the 
German association of kidney centres (DN), the German 
society of nephrology (DGfN) and additional medical 
associations taking part in the apheresis working group 
(The German Society for Combating Dyslipidemia and 
its Associated Illnesses (DGFF e. V.—Lipid-League), the 
German Cardiac Society (DGK), the German Society for 
Clinical Chemistry and Laboratory Medicine e. V. (DGKL), 
the International Society for Apheresis) initiated the first 
national German Lipoprotein Apheresis Registry (DLAR). 
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variables are recorded: Mean concentration of lipid levels 
(cholesterol, triglyceride, LDL cholesterol (LDL-C), high-
density lipoprotein cholesterol, Lp(a)), mean reduction rates 
of lipids before and after apheresis, mean treated volume 
of blood/plasma, type and frequency of adverse effects and 
complication, accompanying medication, type and num-
ber of vascular events involving the heart (Major adverse 
coronary events (MACE)) or other organs (Major adverse 
non-coronary events (MANCE)) observed during therapy 
in comparison with anamnestic data, lipidological diagno-
sis and comorbidities as well as a description of vascular 
accesses. The scientific advisory board of the DLAR has 
requested at least one complete LA treatment to be recorded 
every 3 months. All new events (MACE, MANCE) occur-
ring under LA therapy have to be documented appropriately 
in the registry. Retracing single patients from the dataset is 
not possible to the funding body, the operator or the service 
providers. Each participating centre has full access to its 
data, which are decoded client-side.
The foundation owned Wissenschaftliches Institut für 
Nephrologie (WiNe—Scientific Institute for Nephrology, 
Düsseldorf, Germany) was commissioned as operator of the 
DLAR. The Stiftung für Nephrologie (Nephrology Founda-
tion) is as funding body of the DLAR responsible for financ-
ing, incorporating project-bound donations of the industrial 
partners involved (B. Braun Avitum GmbH, DIAMED 
Medizintechnik, Fresenius Medical Care Deutschland 
GmbH, Kaneka Pharma Europe N.V., Miltenyi Biotec 
GmbH; Germany) as well. Therefore, no costs are created 
for the participating centres. The company BioArtProducts 
GmbH (B.A.P., Rostock, Germany) was commissioned with 
the technical implementation of the registry as well as the 
preliminary statistical data analysis. In assessing data qual-
ity and analysis, WiNe is supported by a scientific advisory 
board, the members of which are listed in the acknowledge-
ments of this publication.
Results
Seven LA centres were selected by the scientific advisory 
board to participate in the pilot phase (Start: 1 October 2011 
to End: 15 May 2012) of the DLAR. Five of the centres sub-
sequently entered data into the registry. For 301 apheresis 
patients, complete data on 455 LA treatments were gath-
ered. Adverse events were recorded for 14 treatments (3 %) 
(failed punctures n = 2, hypotension n = 2, nausea n = 1, 
abdominal pain n = 1, technical difficulties n = 1, other n = 6). 
For the patients, 301 diagnosis related groups were entered 
(CHD n = 280, heart transplantation n = 5, PAD n = 13, cere-
brovascular diseases n = 3).
From the start of the registry in May 2012 until October 
2014, the number of registered patients receiving chronic 
LA treatment increased continuously from 301 (pilot phase) 
All technical requirements, input forms and database sys-
tems were implemented by BioArtProducts GmbH. The 
responsible Nephrology Foundation has commissioned its 
Wissenschaftliches Institut für Nephrologie (WiNe—Sci-
entific Institute for Nephrology) as operator of the DLAR. 
With WiNe in this position, German data protection laws are 
met and funding has been secured until 2019.
In addition to the scientific interest, the initiative has been 
motivated to meet the demand of the G-BA for systematic 
investigation and analysis of the permanent impact of LA 
therapy with regard to the occurrence of additional cardio-
vascular events and, if applicable, associated mortality. It 
aims to validate and thus secure LA methods as established 
lipid-lowering therapy and to justify the comparably high 
costs of therapy for a relatively low number of LA patients. 
An originally required randomised, prospective study on the 
extracorporeal removal of Lp(a), (The ELAILa trial) involv-
ing a control group not undergoing LA was refused by the 
ethical review committee of the Berlin Charité, Germany.
In a pilot phase starting October 2011, data were col-
lected by seven larger apheresis centres (AC). The expe-
riences gathered here were employed to optimise the data 
entry process of the registry towards the version currently in 
use. Since the end of the pilot phase in March 2012, limited 
funding currently fixes the project runtime from April 2012 
to December 2016, which is actually prolonged to June 
2019. Participation in the registry is voluntary and free of 
charge for the participants.
The users of the registry contribute to add a large sample 
to the hitherto positive results of single observations and 
existing publications. Furthermore, they receive higher 
quality data on patient population, morbidity, reduction 
rates, treatment volumes, accompanying medication and 
compatibility [3, 4]. The registries meet the requirements of 
the G-BA for a systematic survey of the LA therapy, techni-
cally equating to quality assurance for the method as well. 
Also, the documented data are suitable to inform the annual 
follow-up applications on continuation of LA therapy to the 
apheresis commission of the respective federal states. How-
ever, this mode of application is currently only officially 
recognised by the Regional Associations of Statutory Health 
Insurance Physicians of Lower Saxony (KVN).
This article presents results of a first, preliminary evalua-
tion of data collected by the DLAR.
Methods and results
Description of the registry
The DLAR is a secure Internet platform providing partici-
pating centres with an input mask for data on treatments 
observing all data law requirements. Here, the following 
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far. Furthermore, some AC have entered patient data but not 
documented any LA treatments.
Of the 991 patients in the register, data recorded prior 
to initiation of LA therapy have been recorded of LDL-C 
concentration for 787 patients and Lp(a) concentrations for 
688 patients, amounting to approximately 10 % of labora-
tory data missing. Patients can be divided in the follow-
ing subgroups: 400 patients with LDL-C > 3.4 mmol/l 
to 991 patients in 96 participating AC (Fig. 1). Of those 
patients included into the DLAR, the diagnosis prior to the 
initialisation of LA therapy is known for 887 only. Of these, 
630 suffered from CHD, 111 from a cerebrovascular insult 
and 146 from PAD. This also led to a distinct increase in 
documented LA treatments to a total of 7946 LA therapies 
(Table 1, Fig. 2).
The currently participating 96 AC are comprising cen-
tres, which attend to more than 100 LA patients as well as 
less than 10 (Table 1). Here, it is remarkable that the data 
recorded in the DLAR are mainly provided by the largest 
AC. It is further to note that there are AC that have regis-
tered with the DLAR but have not entered any patients so 






Participating centres 96 96 96 96
Total collected patients 991 918 873 680
 100+ Patients 3 1 1 1
 50–99 Patients 3 5 4 3
 10–49 Patients 16 14 14 10
 1–9 Patients 38 38 36
 0 Patient 36 38 41
Collected treatment 7946 6535 3158 3752
 Centres with 100+ 
treatments
14 13 12
 Centres with 10–99 
treatments
18 16 17
 Centres with 0–9 
treatments
64 67 67
Fig. 2 Number of documented lipoprotein apheresis treatments over 
the time period from May 2012 to October 2014
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than one. It is remarkable that the most reported adversary 
effects were failed punctures and no direct side effects of the 
LA therapy were documented.
Discussion
The constant increase in the numbers of participating 
AC and documented patients since the start of the DLAR 
(130 mg/dl) (50.8 %) and 387 patients with LDL-
C < 3.4 mmol/l (130 mg/dl) (49.2 %), respectively and 539 
patients with LDL-C > 2.6 mmol/l (100 mg/dl) (68.5 %) and 
248 patients with LDL-C < 2.6 mmol/l (100 mg/dl) (31.5 %) 
(n = 787), respectively and 348 patients with Lp(a) > 60 mg/
dl (50.6 %) (n = 688).
This Lp(a)-subgroup (n = 348) is divided into 86 patients 
with Lp(a) > 60 mg/dl and LDL-C > 3.4 mmol/l (130 mg/dl) 
(24.7 %) and 262 patients with Lp(a) > 60 mg/dl and LDL-
C < 3.4 mmol/l (130 mg/dl) (75.3 %), respectively, and 172 
patients with Lp(a) > 60 mg/dl and LDL-C > 2.6 mmol/l 
(100 mg/dl) (49.4 %), respectively, and 176 patients with 
Lp(a) > 60 mg/dl and LDL-C < 2.6 mmol/l (100 mg/dl) 
(50.6 %).
Reduction rates of LDL-C and Lp(a) under chronic LA 
treatment were recorded in the DLAR (Fig. 3). Furthermore, 
existing data allowed the creation of a sample taking in addi-
tion the haematocrit-corrected LDL-C and Lp(a) reduction 
into account (Fig. 4—online). All LA recorded showed a 
reduction of the lipoproteins LDL-C and Lp(a) by more than 
60 %. A pronounced haemodilution effect seems to be absent.
For the time period from 2011 to 2014, preliminary anal-
ysis finds a reduction of MACE by 90 % as well as a reduc-
tion in MANCE by 69 % for LA patients in the registry.
Over the course of the year 2013, adversary effects were 
recorded for 88 (2.93 %) patients, where in 70 (2.33 %) cases 
exactly one effect was reported and in 18 (0.6 %) more than 
one. During 2012, the total was 49 (2.98 %), 36 (2.19 %) of 
which with one adversary effect and 13 (0.79 %) with more 
Fig. 3 Reduction rates of low-density lipoprotein cholesterol (left) and lipoprotein(a) (right) under chronic lipoprotein apheresis treatment over 
the time period from December 2011 to October 2014
 
Fig. 4 Haematocrit-corrected reduction of S-LDL + S-Lp(a) concen-
trations in percentage after lipoprotein apheresis over the time period 
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quality as well. At the moment however this project lack 
financial support.
Conclusion
The DLAR represents an important means to meet require-
ments for quality assurance of LA therapy expressed both 
by the G-BA as well as users. Already now the existing data 
document the high quality of LA treatment and thus could 
justify the introduction of a nationally standardised rate of 
refund for LA in Germany by the National Association of 
Statutory Health Insurance Physicians.
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